Kidney: Biopsy | ||
Surgical Pathology Cancer Case Summary (Checklist) | ||
*Procedure | ||
*____ Biopsy, needle core | ||
*____ Incisional biopsy, wedge | ||
*____ Other (specify): ______________________________ | ||
*____ Not specified | ||
*Specimen Laterality | ||
*____ Right | ||
*____ Left | ||
*____ Not specified | ||
*Histologic Type | ||
*____ Clear cell renal cell carcinoma | ||
*____ Multilocular cystic renal cell carcinoma | ||
*____ Papillary renal cell carcinoma | ||
*____ Chromophobe renal cell carcinoma | ||
*____ Carcinoma of the collecting ducts of Bellini | ||
*____ Renal medullary carcinoma | ||
*____ MiTF/TFE family translocation-associated renal cell carcinoma | ||
*____ Carcinoma associated with neuroblastoma | ||
*____ Mucinous tubular and spindle cell carcinoma | ||
*____ Tubulocystic renal cell carcinoma | ||
*____ Renal cell carcinoma, unclassified | ||
*____ Clear cell papillary renal cell carcinoma | ||
*____ Acquired cystic disease-assoicated renal cell carcinoma | ||
*____ Other (specify): ______________________________ | ||
*Sarcomatoid Features | ||
*____ Not identified | ||
*____ Present | ||
*Specify percent sarcomatoid element: __________ % | ||
*Histologic Grade (Fuhrman Nuclear Grade) | ||
*____ Not applicable | ||
*____ GX: Cannot be assessed | ||
*____ G1: Nuclei round, uniform, approximately 10 µm; nucleoli inconspicuous or absent | ||
*____ G2: Nuclei slightly irregular, approximately 15 µm; nucleoli evident | ||
*____ G3: Nuclei very irregular, approximately 20 µm; nuclei large and prominent | ||
*____ G4: Nuclei bizarre and multilobulated, 20 µm or greater; nucleoli prominent; chromatin clumped | ||
*Additional Pathologic Findings | ||
*____ None identified | ||
*____ Other pathology present (specify): ______________________________ | ||
* Data elements with asterisks are not required. However, these elements may be clinically important but are not yet validated or regularly used in patient management. Adapted with permission from College of American Pathologists, “Protocol for the Examination of Specimens from Patients with Invasive Carcinoma of Renal Tubular Origin.” Web posting date October 2009, www.cap.org. |
Protocol for Renal Tubular Cancer Specimens
Protocol for Renal Tubular Cancer Specimens